Incyte Corp - INCY STOCK NEWS

Incyte (NASDAQ:INCY) has announced plans to present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago from April 25-30. The presentations will showcase research across multiple programs, including treatments for myeloproliferative neoplasms, ovarian cancer, and other solid tumors.

Key presentations include data on INCB177054, a novel DGKα/ζ dual inhibitor; INCA33890, a bispecific antibody targeting PD-1 and TGFβR2; and INCB057643, a BET protein inhibitor showing improvements in bone marrow function and effects on myelofibrosis treatment. The research demonstrates Incyte's ongoing efforts to advance its pipeline and transform cancer treatment approaches.

Incyte (NASDAQ: INCY) has announced the presentation of multiple abstracts featuring new data from its oncology portfolio at the 2025 ASCO Annual Meeting (May 30 – June 3, 2025) in Chicago.

The presentations will showcase data from both approved medicines and early-stage pipeline, including:

• Phase 1 study results of INCB123667, a selective CDK2 inhibitor, for advanced platinum-resistant ovarian cancer
• Phase 2 study results of pemigatinib for pre-treated glioblastoma with FGFR1-3 alterations
• Multiple studies on retifanlimab in treating various cancers including anal canal carcinoma and Merkel cell carcinoma
• Data on INCB057643, a BET inhibitor, for myelofibrosis treatment

Incyte (Nasdaq: INCY) has scheduled its first quarter 2025 financial results announcement for April 29, 2025. The company will release its Q1 2025 financial results via press release at 7:00 a.m. ET, followed by a conference call and webcast at 8:00 a.m. ET.

Investors can access the conference call through domestic (877-407-3042) and international (201-389-0864) dial-in numbers using conference ID 13753168. A replay will be available for 30 days, and the webcast with slides can be accessed at Investor.Incyte.com, remaining available for 90 days.

Incyte (INCY) has announced the granting of restricted stock unit awards (RSUs) to 24 new employees, totaling 20,334 shares of company common stock. The grants were made under the company's 2024 Inducement Stock Incentive Plan, with both grant date and vesting commencement date set for April 1, 2025.

The awards were approved by the compensation committee of Incyte's board of directors as an inducement for new employees joining the company, in compliance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares vesting annually, contingent upon continued employment.

Incyte (INCY) announced positive topline results from two Phase 3 clinical trials (STOP-HS1 and STOP-HS2) evaluating povorcitinib, an oral JAK1 inhibitor, for treating moderate to severe hidradenitis suppurativa (HS).

Both studies met their primary endpoints at 45 mg and 75 mg doses, demonstrating a significantly higher proportion of patients achieving Hidradenitis Suppurativa Clinical Response (HiSCR50) compared to placebo. The drug showed particular efficacy in patients previously exposed to biologics.

Key achievements include:

• Deep levels of clinical response (HiSCR75)
• Reduction in flares
• Decrease in Skin Pain NRS score
• Rapid onset of response

The safety profile remained consistent with previous data, with no new safety signals observed. Both doses were well tolerated. Incyte plans to submit these results for worldwide regulatory approval.

Eli Lilly (NYSE: LLY) reported promising Phase 3 BRAVE-AA-PEDS study results for baricitinib in treating adolescents with severe alopecia areata (AA). The study involved 257 patients aged 12-18 years.

Key findings at Week 36 showed that 42.4% of patients receiving 4mg baricitinib achieved 80% or more scalp hair coverage, compared to 4.5% on placebo. The 4mg dose group also demonstrated significant improvements with 50% achieving eyebrow regrowth and 42.9% showing eyelash regrowth.

Results suggest faster hair regrowth in adolescents compared to adults, with comparable efficacy achieved at 36 weeks versus 52 weeks in adult studies. The most common side effects included acne, influenza, and upper respiratory tract infection, with no major adverse events reported.

Incyte (INCY) announced results from Phase 3 TRuE-PN clinical trials evaluating ruxolitinib cream 1.5% (Opzelura®) for prurigo nodularis (PN) treatment. The TRuE-PN1 study met its primary endpoint, with 44.6% of patients achieving significant itch improvement versus 20.6% in the vehicle control group at Week 12.

Key secondary endpoints were also met, including:

• 15.8% vs 3.9% achieved Investigator's Global Assessment Treatment Success
• 11.9% vs 2.9% achieved overall treatment success
• 29.7% vs 12.7% showed significant itch improvement at Week 4

In the TRuE-PN2 study, while showing positive trends across secondary endpoints, the primary endpoint did not reach statistical significance due to high placebo response. The safety profile remained consistent with previous data. These results will inform upcoming regulatory discussions.

Incyte (INCY) has announced the granting of restricted stock unit awards (RSUs) to 16 new employees, totaling 13,351 shares of company common stock. The grants were made under the company's 2024 Inducement Stock Incentive Plan, with both grant date and vesting commencement date set for March 3, 2025.

The awards were approved by the compensation committee of Incyte's board of directors as an inducement for new employees joining the company, in compliance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest in four equal annual installments of 25% each, contingent upon continued employment with the company.

Incyte (NASDAQ: INCY) announces multiple data presentations at the upcoming 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, March 7-11, 2025. The presentations will feature new data from their dermatology portfolio, including:

- Late-breaking Phase 3 data for ruxolitinib cream (Opzelura®) in prurigo nodularis from the TRuE-PN1 study

- Multiple presentations on ruxolitinib cream in atopic dermatitis, including long-term safety data from TRuE-AD1 and TRuE-AD2 Phase 3 studies, treatment patterns, and 52-week disease control in children aged 2-11 years

- Data for axatilimab (Niktimvo™) in patients with dermatologic manifestations of chronic graft-versus-host disease (GVHD)